RSC Medicinal Chemistry

Papers
(The H4-Index of RSC Medicinal Chemistry is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Donepezil-based rational design of N-substituted quinazolinthioacetamide candidates as potential acetylcholine esterase inhibitors for the treatment of Alzheimer's disease: in vitro and 98
Design, synthesis and in vitro evaluations of new cyclotriphosphazenes as safe drug candidates62
Effect of mono-guanidine-like derivatives on platelet aggregation and tumour cell induced platelet aggregation58
Oxazole and isoxazole-containing pharmaceuticals: targets, pharmacological activities, and their SAR studies52
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective49
Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs46
Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance40
Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update40
Design, synthesis, antimicrobial activity, stability, and mechanism of action of bioresorbable ceragenins38
Development of benzofuran-derived sulfamates as dual aromatase-steroid sulfatase inhibitors (DASIs): design, synthesis and biological evaluation31
AiZynth impact on medicinal chemistry practice at AstraZeneca31
Biocompatible glycolipid derived from bhilawanol as an antibiofilm agent and a promising platform for drug delivery31
Back cover30
Back cover29
Contents list29
Contents list27
Contents list26
Introduction to the antibiotic and antiviral compounds themed collection24
Contents list24
Contents list22
Novel pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity21
New azole derivatives linked to indole/indoline moieties combined with FLC against drug-resistant Candida albicans21
Back cover21
0.087647914886475